In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Approved by the FDA in May 2024, Moderna’s mRNA shot, mRESVIA, only generated $10 million in sales during the third quarter, its RSV season debut. Besides the impact of a narrowed CDC policy ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...

Moderna’s mRESVIA is the first FDA-approved mRNA therapy designed to prevent respiratory syncytial virus (RSV) in adults 60 and over. The EU, Norway, Iceland, and Qatar have also approved it.

Moderna's trailing-12-month revenue is just ... And despite widespread outbreaks of respiratory syncytial virus (RSV), the recent approval of its RSV vaccine has also not moved the needle much.

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.